The authors would like to thank the following individuals for their contributions to this manuscript: Ossama Ashraf Ahmed, Noha O. Mansour, Doaa H. Abdelaziz, Mohamed Hassan Ahmed Fouad, Mohamed Sayed Hantera, and Hany M. Dabbous. The American Society of Tropical Medicine and Hygiene has waived the Open Access fee for this article due to the ongoing COVID-19 pandemic and has assisted with publication expenses.
Gordon CJ et al., 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 295: 6785–6797.
Uzunova K, Filipova E, Pavlova V, Vekov T, 2020. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother 131. doi: 10.1016/j.biopha.2020.110668.
Sheahan TP et al., 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9: 110668. doi: 10.1126/scitranslmed.aal3653.
Wang M et al., 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30: 269–271.
Pizzorno A et al., 2020. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell Reports Med 1: 100059.
U.S. Food and Drug Administration, 2020 FDA Approves First Treatment for COVID-19. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. Accessed May 22, 2021.
U.S. Food and Drug Administration, 2020 FDA’s Approval of Veklury (Remdesivir) for the Treatment of COVID-19—The Science of Safety and Effectiveness. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness. Accessed May 22, 2021.
Spinner CD et al., 2020. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324: 1048–1057.
Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T, 2021. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur J Pharmacol 897: 173926.
WHO Solidarity Trial Consortium, 2021. Repurposed antiviral drugs for COVID-19—interim WHO Solidarity Trial results. N Engl J Med 384: 497–511.
Egyptian National Guidelines for COVID-19 , 2020. Available at: https://hiph.alexu.edu.eg/images/egyptian_national_guidelines_covid-19.pdf.pdf.pdf. Accessed May 15, 2021.
Wang C, Wang Z, Wang G, Lau JYN, Zhang K, Li W, 2021. COVID-19 in early 2021: current status and looking forward. Signal Transduct Target Ther 6: 1–14.
Rees EM et al., 2020. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med 18. doi: 10.1186/s12916-020-01726-3.
Olender SA et al., 2020. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. Clin Infect Dis. doi: 10.1093/cid/ciaa1041.
Wang Y et al., 2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395: 1569–1578.
Dabbous HM et al., 2021. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol 166: 949–954.
Soni M, Gopalakrishnan R, Vaishya R, Prabu P, 2020. D-dimer level is a useful predictor for mortality in patients with COVID-19: analysis of 483 cases. Diabetes Metab Syndr 14: 2245–2249.
Sharifpour M, Rangaraju S & Liu M et al., 2020. C-reactive protein as a prognostic indicator in hospitalized patients with COVID-19. PLoS One 15: e0242400.
Hsu C-Y, Lai C-C, Yen AM-F, Chen SL-S, Chen H-H, 2020. Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study. medRxiv doi: 10.1101/2020.05.02.20088559.
Group TWREAfC-TW , 2020. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324: 1330–1341.